Stock MIST MILESTONE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.57 USD +1.95% Intraday chart for Milestone Pharmaceuticals Inc. -3.68% -5.99%
Apr. 08 Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting CI
Mar. 28 Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
AQ
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
AQ
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
CI
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
AQ
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
AQ
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA
MT
Milestone Pharmaceuticals : Corporate Presentation
PU
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
AQ
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
CI
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
AQ
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Milestone Pharmaceuticals : Corporate Presentation
PU
Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating
MT
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
AQ
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
AQ
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
AQ
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA
DJ
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
AQ
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIST Stock
  4. News Milestone Pharmaceuticals Inc.